Datasets:

---

Recag

/

Rp_CommonC_110

like 0

ERROR: type should be string, got "https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMzk2NDI1LW92ZXJ2aWV3\nDrugs & Diseases > Radiology\nSynovial Sarcoma Imaging\nUpdated: Mar 02, 2019\nAuthor: Michael J Duh, MD; Chief Editor: Felix S Chew, MD, MBA, MEd more...\nSections Synovial Sarcoma Imaging\nPractice Essentials\nSynovial sarcoma constitutes 8-10% of all sarcomas and usually involves the extremities (as demonstrated in the images below), especially the lower extremities around the knees. Synovial sarcoma is frequently misdiagnosed as a benign condition because of its often small size, slow growth, and well-defined appearance. This malignancy is driven by a translocation between SS18 and SSX 1, 2, or 4 (hybrid transcription factor SS18:SSX). Approximately 1,000 cases a year are diagnosed n the United States, most commonly between 15 and 30 years of age. [1, 2, 3, 4, 5]\nAs with all sarcomas, magnetic resonance imaging (MRI) is the modality of choice because of its excellent tissue contrast and ability to depict the lesion in multiple planes. MRI is useful for evaluating the extent of the tumor and its involvement with adjacent soft-tissue structures. For instance, MRI is helpful in the differentiation of tumor from muscle tissue and in depicting the involvement of neurovascular structures, tendons, fascial/fat planes, and bone marrow. MRI is also helpful for the differentiation of recurrent soft-tissue tumors from postsurgical or postirradiation changes. Computed tomography (CT) scanning can be used in lieu of MRI in patients who have contraindications to MRI (eg, claustrophobia, pacemakers, aneurysm clips). As with MRI, CT scanning can be useful for determining the gross anatomic extent of the tumor, and this modality is also especially useful for depicting calcifications, bone invasion, or periosteal reaction. [6, 7, 8, 9, 10, 11, 12, 13, 14]\nAlthough MRI has proven to be valuable for the detection and staging of soft-tissue tumors, MRI signal intensity characteristics are usually nonspecific for a histologic diagnosis, with some exceptions (eg, lipomas, some liposarcomas, pigmented villonodular synovitis). Although certain signs can suggest synovial sarcoma in the differential diagnosis, MRI findings are by no means pathognomonic, and histologic analysis of the involved tissue is usually required for definitive diagnosis.\n(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. [15, 16] In a study by Lisle et al, (18)F-FDG-PET-derived maximum standard uptake value (SUVmax) ranged from 1.2 to 13.0 (median, 4.35). According to the study findings, pretherapy tumor SUV(max) predicted overall survival and progression-free survival. Patients who had an SUVmax greater than 4.35 were shown to have a decreased disease-free survival and were therefore at high risk for local recurrence and metastatic disease. [15]\n(See the images below.)\nLateral radiograph of the foot in a 60-year-old man who presented with a mass on the dorsum of his left foot. The radiograph shows a soft-tissue mass that is anterior to the talus and without obvious underlying bone erosion. Subtle faint calcifications are seen within the mass.\nAxial T1-weighted magnetic resonance image of the thigh in a 45-year-old man who presented with a large, right midthigh mass. The anterior mass is well circumscribed, with mostly homogeneous isointensity relative to the muscle. Scattered, small, hyperintense foci probably represent hemorrhage. The fat plane between the mass and the femur is preserved.\nSynovial sarcoma tumors can appear small, especially those in the hands or head and neck regions, [17, 18, 19] where they come to medical attention earlier. Often, the small size, well-defined margins, and sometimes homogeneous appearance of synovial sarcoma can lead to misdiagnosis as a benign lesion. Berquist et al found that synovial sarcoma was the malignant soft-tissue sarcoma most frequently misdiagnosed as benign. [20] Small, superficial, solid lesions should be approached as a possible sarcoma unless strong signs prove otherwise. [2, 21]\nBiopsy guidance\nThe choice of the imaging modality for biopsy guidance depends on the availability of the equipment, the expertise of the radiologist, and the characteristics of the lesion. CT scanning guidance is optimal for the biopsy of small lesions or those lesions that are near neurovascular bundles or other critical structures. Fluoroscopy is a real-time imaging modality that can be used for the biopsy of larger lesions that are easily seen on 2-dimensional radiographs. Ultrasonography can be used in select cases in which the lesion is more superficial and easily visible on real-time images. [21, 22, 23]\nThe advantages of ultrasonography over CT scanning include the following: (1) continuous real-time visualization of the needle, (2) the ability to assess regions of viable tissue by using color-flow Doppler imaging, (3) the lack of ionizing radiation, (4) the availability of ultrasound scanners, (5) the reduced procedural time, and (6) overall cost-effectiveness. In some cases in which the tumor is not easily seen on CT scans or in which visualization of the tumor in several planes is desired, MRI-guided biopsy can be performed. [21, 22, 23]\nRadiography is often the initial study obtained for the evaluation of synovial sarcoma. In 50% of patients with synovial sarcoma, radiographic findings are interpreted as normal (as potentially could occur with the image below). If an abnormality is present, the radiograph may reveal a well-defined, round or lobulated soft-tissue mass that averages approximately 8 cm in its largest dimension. [6]\nLateral radiograph of the femur in a 45-year-old man who presented with a large, right midthigh mass. This radiograph is remarkable only for a subtle soft-tissue prominence on the anterior aspect of the thigh. No calcifications are depicted.\nApproximately 30% of patients have calcifications that are detectable radiographically (as in the images below). The calcifications may be focal or spread throughout most of the tumor, and they may appear fine, stippled, or opaque.\nAnteroposterior radiograph of the hip in a patient who presented with a mass in the region of the left hip. Opaque, masslike calcifications overlying the femoral neck and inferior pubic ramus are seen.\nUncommonly, tumors can erode bone. Adjacent periosteal reaction can be seen in as many as 20% of patients. Distant metastases to bone are usually of the lytic and/or mixed variety.\nWhen the neoplasm is near a joint and causes limitation of movement, periarticular osteoporosis may be seen.\nCT scan findings are nonspecific and usually demonstrate a single round or lobulated mass with a soft-tissue density. The lesions measure approximately 3-12 cm in their largest dimension and are usually found near a joint. Masses in the head and neck or distal extremities are smaller at presentation, presumably secondary to an early mass effect.\nThe mass is usually well defined (as in the CT scans below) but can occasionally appear infiltrative and can be homogeneous and show homogeneous enhancement, particularly in smaller lesions; alternatively, if hemorrhage or necrosis has occurred, the lesion may be multiloculated and show heterogeneous enhancement. [18, 24, 9]\nComputed tomography scan through the right thigh. This image demonstrates a round, noncalcified, well-circumscribed mass that displaces, rather than invades, the surrounding muscles. The mass appears to be separate from the bone.\nComputed tomography scan of the thigh in a 45-year-old man who presented with a large, right midthigh mass. A well-defined mass is seen on the anterior aspect of the thigh and appears to be mostly isodense relative to the muscle, with curvilinear areas of slightly increased density. The mass appears apposed to the underlying bone.\nCalcifications are demonstrated in 30% of patients [1] ; typically, diffuse punctate calcifications are revealed. These are often more concentrated at the periphery than at the center. Extensive calcifications can be similar in appearance to osteosarcoma or a calcified chondroid lesion. Densely calcified lesions, when found near a joint, may simulate tumoral calcinosis. Areas of calcification are seen in the image below.\nComputed tomography scan of the hip in a patient who presented with a mass in the region of the left hip. The scan was obtained through the mass and demonstrates masslike areas of calcification within the muscle density in the region of the left obturator externus muscle.\nInvolvement of the adjacent bone can cause changes, including cortical invasion with a wide zone of transition, bone remodeling from pressure erosion, and/or adjacent periosteal reaction.\nSynovial sarcoma tumors tend to be large, averaging approximately 8 cm in their largest dimension, which is usually parallel to the long axis of the body. Approximately 91% of patients have a well-defined, ovoid lesion with rounded or gently lobulated margins (see the image below). [24] The effect on adjacent structures is usually displacement, rather than invasion or destruction. [9]\nMost tumors display a heterogeneous intermediate signal intensity on T1-weighted MRIs. Lesions smaller than 5 cm are more likely to have a predominantly homogeneous signal intensity that is similar to that of the adjacent muscle (as in the above image). Larger lesions are most often heterogeneous secondary to extensive areas of hemorrhage and necrosis, a characteristic seen in the image below.\nSagittal T1-weighted magnetic resonance image of the thigh in a patient with a mass in the anterior left upper thigh and/or inguinal region. The image shows large areas of hemorrhage and necrosis, with intermediate signal intensity on a background of a muscle-intensity mass.\nOn T2-weighted images, lesions are usually hyperintense, with a signal intensity similar to or higher than that of fatty tissue (as in the first image below). Considerable inhomogeneity is demonstrated in 82% of lesions, with cystic components seen in 77% (as demonstrated in the second and third images below). Cystic components with striking fluid-fluid levels are demonstrated in 18% of tumors. [24]\nSagittal T2-weighted magnetic resonance image of the foot in a 60-year-old man who presented with a mass on the dorsum of his left foot. The mass shows predominantly high signal intensity that is hyperintense relative to fat. Scattered areas of hypointensity probably represent calcifications.\nCoronal T2-weighted magnetic resonance image of the thigh in a 45-year-old man who presented with a large midthigh mass on the right. On this T2-weighted image, the mass has become markedly heterogeneous, with high signal intensity depicting cystic regions of hemorrhage and necrosis. Note that portions of the mass are hyperintense relative to the subcutaneous fat. The location of the mass is somewhat atypical because it is centered at the level of the midshaft rather than near a joint.\nAxial T2-weighted magnetic resonance image of the hip in a patient with a mass in the anterior left upper thigh and/or inguinal region. The mass is inseparable from the underlying femoral cortex and contains strikingly hyperintense cystic areas with irregular septa of intermediate signal intensity.\nApproximately one third of lesions demonstrate the \"triple signal pattern\" on T2-weighted images; this pattern consists of a combination of (1) hyperintense fluid within cystic components, with or without fluid levels, (2) intermediate signal tissue similar in intensity to that of muscle, and (3) slightly hypointense tissue similar in intensity to that of fibrous tissue.\nApposition to bone surfaces without a clear plane of separation is seen in 50-59% of cases, with clear bone erosion (as seen in the superior talus in the image below) or destruction in 22%. Calcifications are not easily seen on MRIs and, when visible, are usually hypointense on all sequences.\nCoronal T1-weighted magnetic resonance image of the foot in a 60-year-old man who presented with a mass on the dorsum of his left foot. A rounded, soft-tissue mass is seen eroding the cortex of the superior talus. The mass is predominantly isointense relative to the muscle, with scattered areas of hyperintensity that are consistent with hemorrhage.\nThe use of gadolinium-based contrast agents has a limited value in the evaluation of synovial sarcomas. On dynamic imaging, malignant soft-tissue masses have been shown to enhance earlier, faster, and more predominantly peripherally than benign lesions. [25] These findings are believed to be secondary to the effects of tumor angiogenesis. Synovial sarcomas usually demonstrate heterogeneous contrast enhancement, with early enhancement of tumor within 7 seconds of arterial enhancement. [25]\nGadolinium-based agents may be helpful in posttreatment MRIs, in which mild, diffuse, nonfocal contrast enhancement is a typical finding. With recurrent disease, focal nodules with homogeneous enhancement and high signal intensity without cystic components are typically seen on T2-weighted images.\nGadolinium-based contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Systemic Fibrosis. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see Medscape.\nUltrasonography does not play a significant role in the evaluation of synovial sarcomas. The imaging characteristics cannot be used to establish a precise diagnosis. Grossly, sonograms can provide information regarding the size and consistency of a soft-tissue mass (eg, differentiating cystic from solid masses or a localized mass from diffuse edema). Most commonly, a well-circumscribed, heterogeneous mass, with or without cystic components, is seen.\nUltrasonography can be useful as a real-time imaging technique for guiding diagnostic needle biopsy, especially in large heterogeneous tumors. Color-flow Doppler ultrasonography reveals blood flow in solid soft-tissue masses. [26] Studies have shown that findings in color-flow Doppler ultrasonography are not specific for differentiating benign from malignant tumors; however, the technique may be useful for monitoring the regression of tumor neovascularity after the administration of chemotherapy or irradiation.\n(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. In a study by Lisle et al, (18)F-FDG-PET-derived maximum standard uptake value (SUVmax) ranged from 1.2 to 13.0 (median, 4.35). According to the study findings, pretherapy tumor SUV(max) predicted overall survival and progression-free survival. Patients who had an SUVmax greater than 4.35 were shown to have a decreased disease-free survival and were therefore at high risk for local recurrence and metastatic disease. [15]\nIn a retrospective study of 212 patients (160 patients with soft-tissue sarcomas, 52 patients with osseous sarcomas), Charest et al evaluated, on the basis of fluorodeoxyglucose (FDG) avidity, the sensitivity of FDG positron emission tomography/CT (PET/CT) scanning for the detection of soft-tissue and osseous sarcomas. Among the study's results, the authors determined that FDG-PET/CT scanning had a sensitivity of 80% for synovial sarcomas. [27]\nAngiography does not play a significant role in the evaluation of synovial sarcoma. Angiography allows the gross evaluation of the tumor's size and vascularity. The tumor appears as a soft-tissue mass with a fine network of tumor vessels and an inhomogeneous capillary blush. The degree of vascularity may vary according to the histopathology.\nOne study reported that monophasic tumors of synovial sarcoma demonstrate a higher degree of neovascularity than do biphasic tumors. [28]\nWhat is synovial sarcoma?\nWhat is the role of imaging in the diagnosis of synovial sarcoma?\nWhy are synovial sarcomas the most frequently misdiagnosed soft-tissue carcinoma?\nWhich imaging modalities should be used to guide biopsy of suspected synovial sarcoma?\nWhich radiology findings are characteristic of synovial sarcoma?\nWhich CT findings are characteristic of synovial sarcoma?\nWhich MRI findings are characteristic of synovial sarcoma?\nWhat is the role of gadolinium-based contrast agents in synovial sarcoma imaging?\nWhat is the role of ultrasonography in the diagnosis of synovial sarcoma?\nWhat is the role of nuclear imaging in the diagnosis of synovial sarcoma?\nWhat is the role of angiography in the diagnosis of synovial sarcoma?\nMurphey MD, Gibson MS, Jennings BT, et al. From the archives of the AFIP: Imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics. 2006 Sep-Oct. 26(5):1543-65. [Medline].\nFerrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004 Aug 1. 101(3):627-34. [Medline].\nStacchiotti S, Van Tine BA. Synovial Sarcoma: Current Concepts and Future Perspectives. J Clin Oncol. 2018 Jan 10. 36 (2):180-187. [Medline].\nStegmaier S, Leuschner I, Poremba C, Ladenstein R, Kazanowska B, Ljungman G, et al. The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. Pediatr Blood Cancer. 2017 Jan. 64 (1):89-95. [Medline].\nFisher C, de Brujin DRH, van Kessel AG. Synovial sarcoma. Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. 2002. IARC Press; Lyon:200–204.\nBaheti AD, Sewatkar R, Hornick JL, Saboo SS, Jagannathan JP, Ramaiya NH, et al. Imaging features of primary and recurrent intrathoracic synovial sarcoma: a single-institute experience. Clin Imaging. 2015 Sep-Oct. 39 (5):803-8. [Medline].\nde Haas RJ, Bonenkamp JJ, Flucke UE, de Rooy JW. Synovial sarcoma of the abdominal wall: Imaging findings and review of the literature. J Radiol Case Rep. 2015 Feb. 9 (2):24-30. [Medline].\nChang KJ, Lim I, Park JY, Jo AR, Kong CB, Song WS, et al. The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma. Nucl Med Mol Imaging. 2015 Mar. 49 (1):33-41. [Medline].\nLiang C, Mao H, Tan J, Ji Y, Sun F, Dou W, et al. Synovial sarcoma: Magnetic resonance and computed tomography imaging features and differential diagnostic considerations. Oncol Lett. 2015 Feb. 9 (2):661-666. [Medline].\nde Oliveira DCL, Pacheco EO, Lopes LTR, do Carmo CC, de Melo ASA. Pericardial synovial sarcoma: radiological findings. Radiol Bras. 2018 May-Jun. 51 (3):201-202. [Medline].\nBaheti AD, Tirumani SH, Sewatkar R, Shinagare AB, Hornick JL, Ramaiya NH, et al. Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients. Br J Radiol. 2015 Feb. 88 (1046):20140608. [Medline].\nAlhazzani AR, El-Sharkawy MS, Hassan H. Primary retroperitoneal synovial sarcoma in CT and MRI. Urol Ann. 2010 Jan. 2 (1):39-41. [Medline].\nO'Sullivan PJ, Harris AC, Munk PL. Radiological features of synovial cell sarcoma. Br J Radiol. 2008 Apr. 81 (964):346-56. [Medline].\nLisle JW, Eary JF, O'Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res. 2009 Jun. 467 (6):1605-11. [Medline].\nShah D, Odedra P. Primary Pleuropulmonary Synovial Sarcoma on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan. Indian J Nucl Med. 2017 Oct-Dec. 32 (4):340-342. [Medline].\nNakajima H, Matsushita K, Shimizu H, et al. Synovial sarcoma of the hand. Skeletal Radiol. 1997 Nov. 26(11):674-6. [Medline].\nHirsch RJ, Yousem DM, Loevner LA, Montone KT, Chalian AA, Hayden RE. Synovial sarcomas of the head and neck: MR findings. AJR Am J Roentgenol. 1997 Oct. 169(4):1185-8. [Medline]. [Full Text].\nRangheard AS, Vanel D, Viala J, et al. Synovial sarcomas of the head and neck: CT and MR imaging findings of eight patients. AJNR Am J Neuroradiol. 2001 May. 22(5):851-7. [Medline]. [Full Text].\nBerquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. AJR Am J Roentgenol. 1990 Dec. 155(6):1251-5. [Medline]. [Full Text].\nSpillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000 Nov 15. 18(22):3794-803. [Medline]. [Full Text].\nRekhi B, Shetty O, Ramadwar M, Rangarajan V, Bajpai J. Role of fine needle aspiration cytology in the diagnosis of a rare case of a poorly differentiated synovial sarcoma with \"Rhabdoid\" features, including treatment implications. Diagn Cytopathol. 2017 Jul. 45 (7):662-667. [Medline].\nWang CH, Xu CC, Jiang JH, Chen YB, Zhan SH. Diagnosis of a rare primary pulmonary synovial sarcoma with endobronchial ultrasound-guided transbronchial needle aspiration. Thorac Cancer. 2016 Nov. 7 (6):684-688. [Medline].\nJones BC, Sundaram M, Kransdorf MJ. Synovial sarcoma: MR imaging findings in 34 patients. AJR Am J Roentgenol. 1993 Oct. 161(4):827-30. [Medline]. [Full Text].\nvan Rijswijk CS, Hogendoorn PC, Taminiau AH, Bloem JL. Synovial sarcoma: dynamic contrast-enhanced MR imaging features. Skeletal Radiol. 2001 Jan. 30(1):25-30. [Medline].\nVan der Woude HJ, Vanderschueren G. Ultrasound in musculoskeletal tumors with emphasis on its role in tumor follow-up. Radiol Clin North Am. 1999 Jul. 37(4):753-66. [Medline].\nCharest M, Hickeson M, Lisbona R, et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009 Jul 11. [Medline].\nLois JF, Fischer HJ, Mirra JM, Gomes AS. Angiography of histopathologic variants of synovial sarcoma. Acta Radiol Diagn (Stockh). 1986 Jul-Aug. 27(4):449-54. [Medline].\nContributor Information and Disclosures\nMichael J Duh, MD Senior Physician, Department of Radiology, Kaiser Permanente\nMichael J Duh, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, Radiological Society of North America\nDisclosure: Nothing to disclose.\nCoauthor(s)\nAmilcare Gentili, MD Professor of Clinical Radiology, University of California, San Diego, School of Medicine; Consulting Staff, Department of Radiology, Thornton Hospital; Chief of Radiology, San Diego Veterans Affairs Healthcare System\nAmilcare Gentili, MD is a member of the following medical societies: American Roentgen Ray Society, Radiological Society of North America, Society of Skeletal Radiology\nSulabha Masih, MD Associate Professor of Diagnostic Radiology, University of California, Los Angeles, David Geffen School of Medicine; Consulting Staff, Department of Radiology, Section of Musculoskeletal Radiology, West Los Angeles Veterans Affairs Medical Center\nSulabha Masih, MD is a member of the following medical societies: American Roentgen Ray Society, Radiological Society of North America, Society of Skeletal Radiology\nSpecialty Editor Board\nBernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand\nMurali Sundaram, MBBS, FRCR, FACR Professor of Radiology and Consulting Staff, Cleveland Clinic Lerner College of Medicine of CWRU\nMurali Sundaram, MBBS, FRCR, FACR is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, Association of University Radiologists, International Skeletal Society, Radiological Society of North America, Society of Skeletal Radiology\nFelix S Chew, MD, MBA, MEd Professor, Department of Radiology, Vice Chairman for Academic Innovation, Section Head of Musculoskeletal Radiology, University of Washington School of Medicine\nFelix S Chew, MD, MBA, MEd is a member of the following medical societies: American Roentgen Ray Society, Association of University Radiologists, Radiological Society of North America\nDavid S Levey, MD Musculoskeletal and Neurospinal Forensic Radiologist; President, David S Levey, MD, PA, San Antonio, Texas\nDavid S Levey, MD is a member of the following medical societies: American Roentgen Ray Society, Bexar County Medical Society, Forensic Expert Witness Association, International Society of Forensic Radiology and Imaging, International Society of Radiology, Technical Advisory Service for Attorneys, Texas Medical Association\nPrint this section\nPrint the entire contents of\nPrint the entire contents of article\nencoded search term (Synovial Sarcoma Imaging) and Synovial Sarcoma Imaging\nRelated Conditions and Diseases\nKaposi Sarcoma Staging\nPathology - Sarcomas of the Head and Neck\nOsteogenic Sarcoma Staging\nSoft Tissue Sarcoma Staging\nSoft Tissue Sarcoma Guidelines\nCardiac Sarcoma\nMedscape Rare Diseases\n\"Major Advance\" Declared in Metastatic Melanoma -- And It's Only Phase 1\nPrecision Oncology in Sarcomas\nCutaneous and Mucosal Manifestations of Viral Diseases\nAccording to Oncologist/Hematologists\n'Surgery Is Never Elegant When Women Are in the OR'\nModerate Intake of Red Meat Tied to Higher Colorectal Cancer Risk\nPoor Diet Linked to 80,000 Cancer Cases in the United States\nVenous Thromboembolism Clinical Practice Guidelines (2019)\nAfter a Patient Death, Top Cancer Center Issues Corrective Plan\n2002 871284-overview Procedures\nProcedures Pathology - Sarcomas of the Head and Neck\n2002 2007127-overview Diseases & Conditions\nDiseases & Conditions Kaposi Sarcoma Staging\nDiseases & Conditions Osteogenic Sarcoma Staging\nDiseases & Conditions Soft Tissue Sarcoma Staging"